SHANGHAI, Feb 11 (Reuters) - Eli Lilly has won Chinese regulators' approval for its drug to treat chronic inflammatory bowel ...
More than a quarter of patients with ulcerative colitis do not receive prior advanced therapy before initiating mirikizumab, ...
Mirikizumab induced a clinical response in 70.3% of patients with moderate-to-severe ulcerative colitis (UC), including those who were previously exposed to other treatments; however, rates of ...
AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis (UC) after the PD-1 agonist flunked a phase 2 study. The San Diego-based biopharma assessed rosnilimab in the midstage study ...
MedPage Today on MSN
Prior biologic use tied to JAK inhibitor benefit in ulcerative colitis
In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...
Appointments strengthen Palisade Bio’s clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative ...
Researchers from the Medical School of Nanjing University hypothesized that in ulcerative colitis, the gut-resident macrophages may be compromised, leading to impaired integrity of the epithelial ...
News Medical on MSN
Ulcerative proctitis not linked to increased rectal cancer risk
People with ulcerative proctitis, a milder and more limited form of ulcerative colitis, are not at higher risk of developing rectal cancer than the general population. This is shown in a new Swedish ...
This is the third FDA approval for Omvoh this year, following approvals for Crohn's disease and a citrate-free formulation INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) ...
A variant of the Aeromonas bacterium promoted colon inflammation in mice and was detected in stools and colon tissue from patients with ulcerative colitis (UC). Suspecting that gut-resident ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results